Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891772181> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2891772181 abstract "Authors Disclaimer: http://medpub-poster.merckgroup.com/ABN2018DISC_MAGNIFY.pdf Background Cladribine tablets (CT) improve clinical and MRI outcomes in patients with active RMS, with significant differences versus placebo after 24 weeks. Objective Describe the design of a study to assess the onset of CT’s clinical and MRI effects in patients with active RMS. Methods MAGNIFY-MS is a 2 year prospective Phase IV trial (including approximately 100 centres in Europe). Eligible patients will receive two years treatment with CT 3.5 mg/kg cumulative dose. Frequent MRI assessments (including lesion count, lesion volume, brain volume and MTR) will be performed at screening, baseline and 1, 2, 3, 6, 12, 15, 18 and 24 months. Various T- and B-cell subtype counts and functional profiling (eg cytokine production) will be assessed. Clinical outcomes will include changes in cognition (SDMT), disability (EDSS/KFS, 9HPT, T25FW), relapses, NEDA, NEDAP and safety at timepoints up to 24 months. Results Aim recruit 300 patients. Primary endpoint: change in the count of combined unique active lesions at end of 6 months versus baseline. Final outcomes expected in 2021. Conclusions MAGNIFY-MS will provide important information on the effects of CT, including early MRI changes, insights into effects on a range of disability and cognition markers, and detailed characterization of immune cell reconstitution. Disclosure statement This study was sponsored by EMD Serono, Inc., a business of Merck KGaA, Darmstadt, Germany (in the USA), and Merck Serono SA – Geneva, an affiliate of Merck KGaA Darmstadt, Germany (ROW)." @default.
- W2891772181 created "2018-09-27" @default.
- W2891772181 creator A5010361421 @default.
- W2891772181 creator A5014165648 @default.
- W2891772181 creator A5020658747 @default.
- W2891772181 creator A5024199819 @default.
- W2891772181 creator A5025462803 @default.
- W2891772181 creator A5031171090 @default.
- W2891772181 creator A5042888061 @default.
- W2891772181 creator A5053531204 @default.
- W2891772181 creator A5057083170 @default.
- W2891772181 creator A5057258783 @default.
- W2891772181 creator A5057445606 @default.
- W2891772181 creator A5071096483 @default.
- W2891772181 creator A5071466585 @default.
- W2891772181 creator A5073011666 @default.
- W2891772181 creator A5076585111 @default.
- W2891772181 date "2018-09-13" @default.
- W2891772181 modified "2023-09-30" @default.
- W2891772181 title "THUR 174 The magnify-ms study: mavenclad® tablets in active rms" @default.
- W2891772181 doi "https://doi.org/10.1136/jnnp-2018-abn.81" @default.
- W2891772181 hasPublicationYear "2018" @default.
- W2891772181 type Work @default.
- W2891772181 sameAs 2891772181 @default.
- W2891772181 citedByCount "0" @default.
- W2891772181 crossrefType "journal-article" @default.
- W2891772181 hasAuthorship W2891772181A5010361421 @default.
- W2891772181 hasAuthorship W2891772181A5014165648 @default.
- W2891772181 hasAuthorship W2891772181A5020658747 @default.
- W2891772181 hasAuthorship W2891772181A5024199819 @default.
- W2891772181 hasAuthorship W2891772181A5025462803 @default.
- W2891772181 hasAuthorship W2891772181A5031171090 @default.
- W2891772181 hasAuthorship W2891772181A5042888061 @default.
- W2891772181 hasAuthorship W2891772181A5053531204 @default.
- W2891772181 hasAuthorship W2891772181A5057083170 @default.
- W2891772181 hasAuthorship W2891772181A5057258783 @default.
- W2891772181 hasAuthorship W2891772181A5057445606 @default.
- W2891772181 hasAuthorship W2891772181A5071096483 @default.
- W2891772181 hasAuthorship W2891772181A5071466585 @default.
- W2891772181 hasAuthorship W2891772181A5073011666 @default.
- W2891772181 hasAuthorship W2891772181A5076585111 @default.
- W2891772181 hasConcept C126322002 @default.
- W2891772181 hasConcept C142724271 @default.
- W2891772181 hasConcept C203092338 @default.
- W2891772181 hasConcept C204787440 @default.
- W2891772181 hasConcept C27081682 @default.
- W2891772181 hasConcept C2989005 @default.
- W2891772181 hasConcept C535046627 @default.
- W2891772181 hasConcept C71924100 @default.
- W2891772181 hasConceptScore W2891772181C126322002 @default.
- W2891772181 hasConceptScore W2891772181C142724271 @default.
- W2891772181 hasConceptScore W2891772181C203092338 @default.
- W2891772181 hasConceptScore W2891772181C204787440 @default.
- W2891772181 hasConceptScore W2891772181C27081682 @default.
- W2891772181 hasConceptScore W2891772181C2989005 @default.
- W2891772181 hasConceptScore W2891772181C535046627 @default.
- W2891772181 hasConceptScore W2891772181C71924100 @default.
- W2891772181 hasLocation W28917721811 @default.
- W2891772181 hasOpenAccess W2891772181 @default.
- W2891772181 hasPrimaryLocation W28917721811 @default.
- W2891772181 hasRelatedWork W2023106976 @default.
- W2891772181 hasRelatedWork W2031157475 @default.
- W2891772181 hasRelatedWork W2036346027 @default.
- W2891772181 hasRelatedWork W2063403384 @default.
- W2891772181 hasRelatedWork W3087975767 @default.
- W2891772181 hasRelatedWork W3195806474 @default.
- W2891772181 hasRelatedWork W3200621203 @default.
- W2891772181 hasRelatedWork W4210425443 @default.
- W2891772181 hasRelatedWork W4220675698 @default.
- W2891772181 hasRelatedWork W4221026952 @default.
- W2891772181 isParatext "false" @default.
- W2891772181 isRetracted "false" @default.
- W2891772181 magId "2891772181" @default.
- W2891772181 workType "article" @default.